ArticleBiotechnology letters2025
The Bacillus subtilis expansin BsEXLX1 enhances cellobiohydrolase I activity on sugar beet pulp as shown by QCM-D.
Article in Biotechnology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Microbial expansins are proteins that are thought to mediate loosening of plant cell wall networks by non-catalytic disruption of non-covalent bonds between polysaccharides, particularly between cellulose chains. As a result, the expansins may facilitate the enzymatic hydrolysis of these polysaccharides. In this work, we used quartz-crystal microbalance with dissipation monitoring (QCM-D) to follow the influence of the Bacillus subtilis expansin BsEXLX1 and an inactive BsEXLX1 mutant (BsEXLX1_D81N) on the enzymatic degradation of never dried sugar beet pulp by a fungal cellobiohydrolase I (Cel7A) EC 3.2.1.176. The presence of the wild type BsEXLX1 enhanced the enzymatic degradation rate on the substrate in a dose dependent manner achieving a doubling of the rate, while the inactive BsEXLX1_D81N mutant exhibited only very limited increase in the degradation rate. This result suggests that the ability of BsEXLX1 to boost the action of Cel7A is linked to the ability of BsEXLX1 to bind to the glucan chains that in turn may increase the distance between two glucan chains enabling increased enzymatic attack.
Indexed as
Identifiers
41196425What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.